Yale Bulletin and Calendar

April 15, 2005|Volume 32, Number 26


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Naltrexone shown to help problem drinkers

Long-acting injections of the drug naltrexone, combined with psychotherapy, significantly reduced heavy drinking in patients being treated for alcohol dependence, according to a study in the Journal of the American Medical Association by a School of Medicine researcher.

"The decision to take medication can wane over time," says Stephanie O'Malley, professor of psychiatry and director of the Division of Substance Abuse Research at the Connecticut Mental Health Center at Yale. "This provides coverage for an entire month."

Alcohol dependence ranks as the fourth leading cause of disability worldwide, as reported by the World Health Organization's Global Burden of Disease project. Nationwide, alcohol is believed to contribute to more than 100,000 preventable deaths a year.

Naltrexone belongs to a class of drugs called opioid antagonists. Although many clinical trials have shown that oral naltrexone can be effective in treating alcohol dependence, its use in clinical practice has been limited, in part because patients have to take the pill daily.

In this trial, conducted at 24 sites, 627 alcohol-dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. All participants received 12 counseling sessions during the six-month study in addition to the medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six month treatment period.

The lead author was Dr. James Garbult of the University of North Carolina School of Medicine. The study was funded by Alkermes Inc., a biotechnology company based in Cambridge, Massachusetts, that manufactures the long-acting naltrexone formulation.

-- By Jacqueline Weaver


T H I SW E E K ' SS T O R I E S

Team uses lasers to control specially modified fruit flies

Financial aid increased for Ph.D. students

Exhibits recount Yale's history and the contributions of its alumni

Visitor Center enjoys pride-of-place as it showcases Yale

Event will bring together staff, students to help city groups

Kim Bottomly has been named as a deputy provost . . .

Zedillo appointed envoy to U.N.'s summer summit

Yale undergraduates make impressive showing in . . .

Cycle of August Wilson plays to conclude with 'Radio Golf'

Next Yale Rep season features new plays . . .

Monthly injections of naltrexone in combination with therapy . . .

Researchers identify a protein in the kidney that regulates . . .

Conference pays tribute to ethicist Margaret Farley

Panel and exhibit mark 30th anniversary of fall of Saigon

Event honors individuals who have contributed to women's health

Conference will consider future of controversial Voting Rights Act

Culture and community

Event highlights new research on AIDS

YALE CANCER CENTER NEWS

Gender studies is topic of final talk in year-long series

In Memoriam: Jack S. Greenberg

Journal addresses SARS and other health issues in China

Calvin Hill opens new art studio

Campus Notes

Golden Girl


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home